Johnson & Johnson (J&J) has secured a US label expansion for its next-generation oncology combination, Akeega, in breast ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

An international group of scientists studying the tendency of intrinsically disordered proteins to form biomolecular condensates report that they have found that the mechanisms involved in ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

The proportion of patients who discontinued treatment was 30.4% in the darolutamide cohort, 40.8% in the enzalutamide cohort, and 46.0% in the apalutamide cohort. Patients with nonmetastatic ...

Dr. Hordinsky discusses how clascoterone 5% topical solution may reshape male AGA management and expand treatment confidence.

Investigators compared PSA90 response between new users of apalutamide vs abiraterone for mCSPC using a large US cohort.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.